How the Netherlands uses innovative finance to drive global health equity*
How the Netherlands uses innovative finance to drive global health equity*
23 September 2025
Netherlands
In the world of global health financing, the Netherlands has provided strategic support for the International Finance Facility for Immunisation (IFFIm) and is a perfect example of how smart, focused investments can deliver powerful results.
In the world of global health financing, the Netherlands has provided strategic support for the International Finance Facility for Immunisation (IFFIm) and is a perfect example of how smart, focused investments can deliver powerful results.
Over the years, the Netherlands has made an outsized impact on global health—leveraging smart, targeted investments to deliver vaccines to millions of children around the world. As a dedicated partner of IFFIm, the Dutch government has used innovative finance as a powerful tool to promote global equity.
The Netherlands joined IFFIm in 2009 as its fifth sovereign donor, committing €80 million over eight years. Since then, its total contributions to IFFIm have reached the equivalent of US$ 487 million over 22 years, helping unlock urgently needed funds for Gavi, the Vaccine Alliance.
At the 2020 Global Vaccine Summit, the Netherlands deepened its commitment by announcing a €325 million contribution to Gavi. Of this, €250 million was channeled through IFFIm to be disbursed over 10 years, maximising impact through frontloading. The package also included €50 million in direct support and €25 million toward Gavi’s extended Matching Fund. In response to the COVID-19 pandemic, the Netherlands stepped up again, committing €70 million to the COVAX Advance Market Commitment (AMC) to help ensure equitable vaccine access in lower-income countries.
Efficiency, accountability, and global impact
The Netherlands’ approach to international development has always prioritised efficiency, transparency, and value for money. These principles are embedded in IFFIm’s model, which turns long-term pledges into immediate resources through Vaccine Bonds, allowing Gavi to respond faster and at scale.
Today, the Netherlands continues to show how innovative finance can turn strategic public funding into life-saving impact. With IFFIm, the Dutch government is not just investing in vaccines; it's investing in global stability, health equity, and a safer world for future generations.
*This article is part of an 11-part series profiling IFFIm donors.
Share this article
Restricted Access Library
The material in this Restricted Access Library is intended to be accessed only by persons with residence within the territory of a Member State of the European Union and is not intended to be viewed by any other persons. The material in this Restricted Access Library is provided by IFFIm for information purposes only and the materials contained herein were accurate only as of their respective dates. Certain information in the materials contained herein is not intended to be, and is not, current. IFFIm accepts no obligation to update any material contained herein.
Persons with residence outside the territory of a Member State of the European Union who have access to or consult any materials posted in this Restricted Access Library should refrain from any action in respect of the securities referred to in such materials and are otherwise required to comply with all applicable laws and regulations in their country of residence.
By clicking Access restricted content: DYNAMIC-LINK-TEXT I confirm that I have read and understood the foregoing and agree that I will be bound by the restrictions and conditions set forth on this page.
The materials in this Restricted Access Library are for distribution only to persons who are not a "retail client" within the meaning of section 761G of the Corporations Act 2001 of Australia and are also sophisticated investors, professional investors or other investors in respect of whom disclosure is not required under Part 6D.2 of the Corporations Act 2001 of Australia and, in all cases, in such circumstances as may be permitted by applicable law in any jurisdiction in which an investor may be located.
The materials in this Restricted Access Library and any documents linked from it are not for access or distribution in any jurisdiction where such access or distribution would be illegal. All of the securities referred to in this Restricted Access Library and in the linked documents have been sold and delivered. The information contained herein and therein does not constitute an offer for sale in the United States or in any other country. The securities described herein and therein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state securities laws.
Each person accessing the Restricted Access Library confirms that they are a person who is entitled to do so under all applicable laws, regulations and directives in all applicable jurisdictions. Neither IFFIm nor any of their directors, employees, agents or advisers accepts any liability whatsoever for any loss (including, without limitation, any liability arising from any fault or negligence on the part of IFFIm or its respective directors, employees, agents or advisers) arising from access to Restricted Access Library by any person not entitled to do so.